Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
A Clinical Evaluation of the RheOx Bronchial Rheoplasty System
This is a prospective, multicenter, single arm and open-label clinical trial to evaluate the performance, effectiveness and safety of RheOx™ system in the treatment of the symptoms of chronic bronchitis in adult moderate to…
- Trial name
- NCT05641207
- Testing
- RheOx™ with the RheOx™ Catheter treated in the trial
- Where
- 7 sites in China
- Volunteers
- 40 people
- Sponsor
- Energenx Medical LTD.
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the IPS System for TLD Therapy in Patients With COPD
Targeted Lung Denervation (TLD) Therapy will be a safe method to ablate the airway nerve trunks that travel parallel to and outside of the main bronchi and into the lungs to achieve targeted lung denervation and potentially…
- Trial name
- IPS-II (NCT01716598)
- Testing
- IPS System
- Where
- 4 sites in Austria, France
- Volunteers
- 15 people
- Sponsor
- Nuvaira, Inc.
Chronic Obstructive Lung Disease
Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal
The purpose of this study s to determine whether treatment with Iodinated Active Charcoal can improve lung function and physical capacity in patients with chronic obstructive lung disorders.
- Trial name
- NCT01404000
- Testing
- Iodinated Active Charcoal (IodoCarb)
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- PharmaLundensis AB
Pulmonary Disease, Chronic Obstructive
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This study is primarily designed to assess the dose response, dose interval, efficacy and safety of three once daily (QD) doses (100mcg, 400mcg and 800mcg) and three twice daily (BID) doses (100mcg, 200mcg and 400mcg,) of…
- Trial name
- NCT01319019
- Testing
- GSK961081, Salmeterol
- Where
- 49 sites in Estonia, Germany and 7 more
- Volunteers
- 437 people
- Sponsor
- GlaxoSmithKline
Lung Cancer, Small Cell Lung Cancer
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma
- Trial name
- NCT05337163
- Testing
- Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination
- Where
- China
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
COPD
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
- Trial name
- NCT00215436
- Testing
- Formoterol Fumarate
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Dey
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease
This will be an open-label, non-randomized multi-center study designed to assess the safety and efficacy of Adipose-derived Stem Cell (ASC) IV implantation.
- Trial name
- NCT02216630
- Testing
- Adipose Derived Stem Cell (ADSC) Therapy
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Kimera Society Inc
Chronic Obstructive Pulmonary Disease
Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD
To evaluate the efficacy and safety of arformoterol tartrate inhalation solution 30μg/4mL QD (two 15μg/2mL dosed in combination) over a 24-hour period compared to arformoterol tartrate inhalation solution 15μg/2 mL BID in…
- Trial name
- NCT00571428
- Testing
- Arformoterol Tartrate Inhalation Solution
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)
To investigate the efficacy and safety of repeated dosing of Levalbuterol over 6 weeks of treatment in COPD.
- Trial name
- NCT00665600
- Testing
- Levalbuterol HCl, Albuterol Sulfate
- Where
- 24 sites in United States, Canada
- Volunteers
- 257 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pulmonary Disease, Chronic Obstructive
Exacerbations Among Patients Receiving Breztri (EROS Study)
EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Retrospective Studies
- Trial name
- NCT06514144
- Testing
- BGF
- Where
- United States
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients
There are three elements to this study: Part A: Single dose escalation in healthy subjects. 6 dose levels of QAK423 are planned in healthy volunteers. Part B: Single dose escalation in patients with mild/moderate COPD.
- Trial name
- NCT01197287
- Testing
- QAK423A
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
COPD, Chronic Obstructive Pulmonary Disease
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care.
- Trial name
- AIRFLOW-4 (NCT07051707)
- Testing
- Targeted Lung Denervation (TLD)
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Nuvaira, Inc.
COPD
7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
This study will characterize the dose response of TD-4208 after 7 days of dosing in subjects with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01704404
- Testing
- TD-4208
- Where
- New Zealand
- Volunteers
- 62 people
- Sponsor
- Mylan Inc.
COPD, Emphysema
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea…
- Trial name
- BREATHE-3 (NCT06891755)
- Testing
- Apreo BREATHE Airway Scaffold, Optimal Medical Management (OMM)
- Where
- 23 sites in United States, Austria and 3 more
- Volunteers
- 250 people
- Sponsor
- Apreo Health, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce…
- Trial name
- MISSION (NCT07587658)
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 754 people
- Sponsor
- Regeneron Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)
Open-label comparative multicentric cohort study in COPD patients with LABA/ICS, switched to either tiotropium/olodaterol and observed for 12 weeks approximately.
- Trial name
- NCT03954132
- Testing
- Spiolto® Respimat®, Triple-Therapy (LAMA/LABA/ICS)
- Where
- 75 sites in Germany
- Volunteers
- 469 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via…
- Trial name
- TRILOGY (NCT01917331)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate, Beclometasone/Formoterol
- Where
- Hungary
- Volunteers
- 1,368 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease (COPD), Asthma
BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA
As part of a post-approval commitment requested by the Ministry of Food and Drug Safety (MFDS), this open-label, single-arm, multicentre, observational Post-Marketing Surveillance (PMS) study aims to characterize the safety…
- Trial name
- Breztri rPMS (NCT07570394)
- Where
- 10 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
COPD
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.
- Trial name
- NCT01794780
- Testing
- LABA based treatment: indacaterol, LAMA based treatment: tiotropium, LABA/ICS based treatment: salmeterol/fluticasone
- Where
- 2 sites in China
- Volunteers
- 2,229 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study
The purpose of this study is to evaluate the efficacy of ARALAST NP A1PI augmentation therapy 120 milligrams per kilogram (mg/kg) body weight (BW)/week compared with an external placebo comparator on the loss of emphysematous…
- Trial name
- NCT04440488
- Testing
- ARALAST NP
- Sponsor
- Shire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.